European Medicines Agency Validates Pfizer and Valneva's Lyme Disease Vaccine Candidate Application

The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate developed by Pfizer and Valneva. The EMA will now begin its assessment of the application, which is supported by Phase 3 trial data showing over 70% efficacy. There are currently no approved human vaccines for Lyme disease.